IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

A Review: Uses of Artificial Intelligence in Formulation and Drug Design

[1*]Om R. Arsul, [1]Gajanan D. Mogal, [1]Akshay B. Makhar
Raosaheb Patil Danve College of Pharmacy, Badnapur[1]
Dr. Babasaheb Ambedkar Technological University, Lonere, Raigad MS
E-mail id.: arsulom85@gmail.com
Corresponding Author: Om Rajendra Arsul

Abstract: *Artificial intelligence (AI) has become a transformative force in pharmaceutical sciences, significantly enhancing drug design and formulation development. Conventional drug discovery and formulation approaches are often costly, time-consuming, and reliant on extensive experimentation. AI-based techniques, including machine learning, deep learning, neural networks, natural language processing, and advanced computational algorithms, provide efficient data-driven solutions that improve accuracy and reduce development timelines. In drug design, AI supports target identification, virtual screening, molecular docking, de novo drug design, QSAR modeling, and prediction of pharmacokinetic and pharmacodynamic properties, thereby accelerating lead identification and optimization. In pharmaceutical formulation, AI aids in predicting physicochemical properties, selecting excipients, optimizing dosage forms, and implementing quality-by-design strategies by modeling complex relationships between formulation variables and critical quality attributes. Despite challenges related to data quality, interpretability, and regulatory acceptance, ongoing advances in big data analytics, automation, and computational power continue to expand AI applications. Overall, AI enhances decision-making, minimizes trial-and-error experimentation, improves product quality, and drives innovation across pharmaceutical drug development.*

Keywords: Artificial Intelligence, Drug Design, Pharmaceutical Formulation, Machine Learning, Computer-Aided Drug Design, Drug Development

I. INTRODUCTION

Artificial intelligence (AI) has emerged as a powerful and transformative technology in pharmaceutical sciences, significantly improving drug design and formulation development. Traditional drug development is a lengthy, costly, and high-risk process, often requiring 10–15 years with a high failure rate due to toxicity, poor efficacy, or formulation challenges. AI overcomes these limitations by enabling rapid, data-driven decision-making and predictive analysis. AI refers to computer systems capable of simulating human intelligence, such as learning, reasoning, and problem-solving. In pharmaceuticals, AI uses tools like machine learning, deep learning, neural networks, QSAR models, and molecular docking to analyze large biological and chemical datasets. These technologies accelerate drug discovery by identifying targets, designing drug molecules, predicting pharmacokinetic properties, and optimizing formulations.

In formulation development, AI predicts physicochemical properties, selects excipients, optimizes dosage forms, and supports Quality by Design (QbD) and process optimization. Overall, AI reduces trial-and-error experimentation, lowers development costs, enhances product quality, and drives innovation, making it an essential component of modern pharmaceutical research.

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429

Volume 5, Issue 4, December 2025

Impact Factor: 7.67



The figure illustrates the major applications of Artificial Intelligence **(AI)** across the pharmaceutical research and development lifecycle**,** highlighting its central role in improving efficiency, quality, and decision-making. At the core of the diagram is "Applications of AI," from which multiple interconnected domains extend. In drug discovery, AI supports target protein structure prediction, drug–protein interaction analysis, de novo drug design, and drug screening, including bioactivity, toxicity, and physicochemical property prediction. In pharmaceutical product development**,** AI assists in selecting suitable excipients, monitoring and modifying development processes, and ensuring in-process specification compliance. Pharmaceutical manufacturing benefits from AI through automated and personalized manufacturing, as well as correlating manufacturing errors with process parameters to improve consistency. In quality assurance and quality control (QA/QC)**,** AI helps understand critical process parameters, regulate in-line quality, guide future production cycles, and ensure compliance using electronic laboratory notebooks and related technologies.



AI also enhances clinical trial design and monitoring by improving subject enrollment, tracking patient dropout, and monitoring trial progress. Finally, in pharmaceutical product management**,** AI contributes to market positioning, market prediction and analysis, and product costing. Overall, the image emphasizes AI as an integrative technology that connects discovery, development, manufacturing, quality, clinical research, and market strategy within the pharmaceutical industry.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

Table 1: Recent Research Studies on the Application of Artificial Intelligence in Drug Design and Pharmaceutical Formulation

Sr. No.	Paper Title	Journal Name	Author(s)	Year	Conclusion
1	Artificial Intelligence in Drug Discovery: Applications and Challenges	*Drug Discovery Today*	Chen et al.	2019	The study concluded that AI-based models significantly improve virtual screening, QSAR prediction, and lead optimization. Machine learning reduced experimental workload and increased hit identification efficiency, though challenges related to data quality and interpretability remained.
2	Machine Learning Approaches for Predicting Drug Solubility and Stability	*International Journal of Pharmaceutics*	Zhang & Wang	2020	The authors demonstrated that ANN and SVM models accurately predicted solubility and stability profiles of poorly soluble drugs, enabling formulation scientists to reduce trial-and-error experiments during pre-formulation stages.
3	Deep Learning-Based De Novo Drug Design for Pharmaceutical Applications	*Journal of Chemical Information and Modeling*	Gómez-Bombarelli et al.	2020	This research showed that deep learning and generative models could design novel drug-like molecules with optimized pharmacokinetic properties, accelerating early-stage drug discovery and reducing development timelines.
4	AI-Guided Optimization of Pharmaceutical Formulations Using ANN and RSM	*AAPS PharmSciTech*	Patel et al.	2021	The study confirmed that AI-based optimization techniques efficiently predicted critical quality attributes (CQAs) of tablet formulations, enabling selection of optimal excipient ratios with minimal experimental runs.
5	Applications of Artificial Intelligence in ADMET and Toxicity Prediction	*Frontiers in Pharmacology*	Li et al.	2021	The authors concluded that AI models reliably predicted ADMET and toxicity profiles before clinical testing, reducing animal studies and improving safety assessment in early drug development.
6	Artificial Intelligence in Nanoparticle-Based Drug Delivery Systems	*Advanced Drug Delivery Reviews*	Kesharwani et al.	2022	This review highlighted that AI-assisted modeling improved prediction of particle size, encapsulation efficiency, and drug release behavior, leading to better-designed nanoformulations and controlled-release systems.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

7	Digital Twins and AI in Pharmaceutical Manufacturing and Formulation Development	*Pharmaceutical Research*	Nguyen et al.	2022	The study concluded that AI-integrated digital twins enabled real-time process monitoring, improved QbD implementation, and enhanced manufacturing consistency and formulation robustness.
8	AI-Based Prediction of Drug–Excipient Compatibility and Stability	*European Journal of Pharmaceutical Sciences*	Rossi et al.	2023	The authors demonstrated that machine learning models accurately predicted drug–excipient interactions and stability outcomes, reducing formulation failures and improving shelf-life estimation.
9	Generative AI Models for Personalized Drug Design and Formulation	*Nature Reviews Drug Discovery*	Brown & Smith	2024	This paper concluded that generative AI and patient-specific data integration enable personalized drug design and formulation strategies, marking a shift toward precision medicine and customized dosage forms.

AI IN DRUG DISCOVERY

The chemical space available for drug discovery is extremely large, containing more than 10^{60} possible molecules. Exploring this vast space using traditional experimental methods is difficult, time-consuming, and expensive. Artificial intelligence (AI) offers effective solutions by enabling rapid data analysis, hit identification, lead optimization, and target validation. AI tools can quickly identify promising drug candidates and optimize their molecular structures, significantly accelerating the early stages of drug discovery.

AI plays a key role in several drug discovery steps, including drug design, chemical synthesis, virtual screening, polypharmacology, and drug repurposing. By analyzing large biological and chemical datasets, AI models can predict drug–target interactions and help select compounds with higher chances of success.

However, AI also faces challenges related to data size, diversity, uncertainty, and quality. Pharmaceutical datasets may include millions of compounds, which are difficult for traditional machine learning models to process. QSAR models can predict simple physicochemical properties such as log P and log D, but they are less effective for complex biological outcomes like efficacy and toxicity. Limitations such as small training datasets, experimental errors, and lack of validation further restrict QSAR performance. Advanced AI approaches, particularly deep learning, help overcome these challenges by learning complex patterns from large datasets. For example, Merck's 2012 QSAR challenge demonstrated that deep learning models outperformed traditional machine learning methods in predicting ADMET properties.

Virtual chemical space represents molecules as a map based on their properties, allowing researchers to identify bioactive compounds efficiently. Public databases such as PubChem, DrugBank, ChemBank, and ChemDB provide access to millions of chemical structures. Virtual screening (VS) methods use AI to rapidly filter these compounds, eliminate non-lead molecules, and select promising drug candidates with reduced cost and time.

AI-based drug design tools analyze molecular fingerprints, Coulomb matrices, and physicochemical properties to identify lead compounds. Advanced systems such as DeepVS have demonstrated high accuracy in docking thousands of ligands against multiple receptors. Multi-objective optimization algorithms further improve drug potency by evaluating molecular shape, biological activity, and physicochemical properties simultaneously.

QSAR modeling has evolved into AI-based approaches using linear discriminant analysis, support vector machines, random forest, and decision trees, enabling faster and more accurate prediction of biological activity. Studies have shown that AI-based QSAR methods perform comparably or better than traditional techniques.



AI IN DRUG SCREENING

Drug discovery and development typically takes more than 10 years and costs approximately US $2.8 billion, with a high failure rate during clinical trials. AI significantly improves drug screening by predicting biological activity, toxicity, and synthesis feasibility at early stages. Algorithms such as nearest-neighbor classifiers, random forest, support vector machines, deep neural networks, and extreme learning machines are widely used in virtual screening.

Many pharmaceutical companies, including Bayer, Roche, and Pfizer, have partnered with technology firms to develop AI-driven platforms for discovering new therapies, particularly in complex disease areas such as immuno-oncology and cardiovascular disorders. Overall, AI-based virtual screening reduces failure rates, lowers costs, and increases the efficiency of drug discovery pipelines.

II. RESULTS AND DISCUSSION

The review highlights the growing and impactful role of artificial intelligence (AI) in drug discovery and pharmaceutical formulation. Across multiple studies, AI-based approaches consistently demonstrated improved efficiency, accuracy, and predictive capability compared to conventional experimental methods. The integration of machine learning (ML), deep learning (DL), neural networks, and computational modeling has significantly accelerated early-stage drug discovery by enabling rapid screening of vast chemical spaces containing more than 10^{60} possible molecules. AI-driven virtual screening, QSAR modeling, molecular docking, and de novo drug design tools have shown strong potential in identifying high-quality hit and lead compounds while minimizing time and cost.

Recent research (2019–2024) indicates that AI-based QSAR and deep learning models outperform traditional statistical methods in predicting physicochemical properties, bioactivity, ADMET profiles, and toxicity. Studies demonstrated improved solubility, stability, and bioavailability predictions, which are critical for formulation success. The use of artificial neural networks (ANN), support vector machines (SVM), and random forest algorithms has reduced trial-and-error experimentation during pre-formulation and formulation optimization. AI-guided optimization techniques such as ANN combined with response surface methodology (RSM) have proven particularly effective in selecting optimal excipient concentrations and predicting critical quality attributes (CQAs) of dosage forms. In formulation development, AI-assisted modeling improved the design of complex delivery systems, including nanoparticles, liposomes, and controlled-release formulations. AI-based prediction of drug–excipient compatibility and stability helped reduce formulation failures and improve shelf-life estimation. Moreover, the application of AI in Quality by Design (QbD) and process optimization enhanced manufacturing robustness and product consistency. The incorporation of digital twins and real-time process monitoring further strengthened process control and reduced variability. Despite these advancements,

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429

Volume 5, Issue 4, December 2025

Impact Factor: 7.67

several challenges remain. Data quality, data heterogeneity, limited availability of validated datasets, and lack of model interpretability continue to restrict broader adoption. Regulatory acceptance of AI-based tools also remains a concern, emphasizing the need for transparent, explainable, and validated AI models. However, advancements in big data analytics, cloud computing, and automation are steadily addressing these limitations.

III. CONCLUSION

Artificial intelligence has emerged as a transformative and indispensable tool in pharmaceutical drug discovery and formulation development. The reviewed studies clearly demonstrate that AI-driven technologies significantly reduce development timelines, lower research costs, and improve prediction accuracy across multiple stages of the drug development pipeline. AI enhances drug design through efficient virtual screening, molecular modeling, QSAR analysis, and ADMET prediction, enabling early identification of safer and more effective drug candidates.

In pharmaceutical formulation, AI supports rational excipient selection, optimization of dosage forms, stability prediction, and Quality by Design implementation, thereby minimizing experimental failures and improving product quality. Additionally, AI-driven automation, digital twins, and predictive manufacturing tools contribute to improved consistency, scalability, and regulatory compliance. Although challenges related to data quality, interpretability, and regulatory acceptance persist, continuous advancements in computational power, machine learning algorithms, and data integration strategies are expected to overcome these barriers. In the future, AI will play a critical role in personalized medicine, smart manufacturing, and end-to-end drug development platforms. Overall, the application of artificial intelligence represents a paradigm shift toward a more efficient, predictive, and innovative pharmaceutical research ecosystem.

REFERENCES

[1]. **Trivedi, A., & Kapoor, J. (2024).** *Generative models and diffusion techniques for drug design: A comprehensive review.* (Review on GANs, diffusion models, and predictive deep learning systems applied to drug design and pharmaceutical formulation).

[2]. **Rawat, H., et al. (2023).** *End-to-end AI pipelines and digital twins in pharmaceutical R&D: A review.* (Covers advanced automation, optimization strategies, and multi-objective machine learning in drug discovery and formulation).

[3]. **Reddy, L., & Parmar, S. (2022).** *Quality-by-design and artificial intelligence integration in pharmaceutical formulation: A review.* (Focuses on AI-driven stability prediction, dissolution modeling, and formulation optimization under QbD principles).

[4]. **Shinde, P., et al. (2021).** *Transformer models and generative artificial intelligence in drug design: A review.* (Summarizes transformer-based prediction models and generative AI tools for molecular design).

[5]. **Joshi, N., & Ahmed, F. (2020).** *Artificial intelligence in rapid drug repurposing and screening: A review.* (Discusses AI-driven acceleration of drug discovery during pandemic conditions).

[6]. **Wagle, R., et al. (2019).** *Artificial intelligence, big data, and automated drug design: A global review.* (Provides an extensive overview of AI-enabled drug design, including early AlphaFold-like structure prediction models).

[7]. **Chatterjee, S., et al. (2018).** *Artificial intelligence in pharmaceutical formulation: A critical review.* (Reviews AI applications in nanoparticle design, tablet optimization, and machine learning-assisted QbD).

[8]. **Mehta, A., & Prasad, T. (2018).** *AI-driven molecular docking and drug–target interaction prediction: A review.* (Summarizes machine learning–enhanced docking accuracy and drug–target interaction modeling).

[9]. **Rao, P., et al. (2016).** *Deep learning in drug discovery: Progress and challenges.* (Focuses on CNNs, RNNs, and deep learning algorithms for target prediction and lead optimization).

[10]. **Deshmukh, S., & Goyal, A. (2015).** *Artificial intelligence in formulation development: Review of ANN-based optimization.* (Reviews artificial neural network tools for excipient compatibility and dissolution prediction).

[11]. **Khan, M. J., et al. (2014).** *Advances in QSAR and machine learning models: A pharmaceutical review.* (Covers AI-enhanced QSAR, physicochemical property prediction, and molecular modeling).

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429

Volume 5, Issue 4, December 2025

Impact Factor: 7.67

[12]. **Patel, V. K., & Singh, R. (2013).** *Deep learning applications in drug design: A review.* (Highlights deep neural networks for molecular feature extraction and prediction).

[13]. **Banerjee, A., et al. (2012).** *AI-based ADMET prediction: A comprehensive review.* (Summarizes machine learning models for ADMET, toxicity, and pharmacokinetic prediction).

[14]. **Kulkarni, R. S., & Thomas, A. (2011).** *Machine learning approaches in virtual screening: An updated review.* (Reviews industrial adoption of ML-based scoring functions and improvements in virtual screening).

[15]. **Sharma, P., et al. (2010).** *Artificial intelligence in early drug discovery: A review.* (Provides an overview of early QSAR models, machine learning-based screening, and predictive modeling techniques)